Payment overview · 2025
General Payments
$521.16
29 reported records · 9 companies
Healthcare provider profile · identity verified
Spencer Matthew Harris, DO
Allopathic & Osteopathic Physicians|Family Medicine · LOUISA, KY · NPI 1376704528
Verified facts
What the public records show
CMS Open Payments records show Spencer Matthew Harris, DO received $521.16 in general payments during 2025 across 29 reported records.
GlaxoSmithKline, LLC. accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $164.54 | 31.6% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $122.46 | 23.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.23 | 10.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.80 | 9.2% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $38.59 | 7.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.61 | 6.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.99 | 4.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.73 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.21 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $521.16 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $164.54 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $78.19 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.35 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.80 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $38.59 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.61 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 837 | 167 |
| Lisinopril | Lisinopril | 725 | 131 |
| Gabapentin | Gabapentin | 668 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 607 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 553 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 501 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 445 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 397 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 341 | 67 |
| Metformin Hcl | Metformin Hcl | 290 | 53 |
| Omeprazole | Omeprazole | 260 | 52 |
| Trazodone Hcl | Trazodone Hcl | 257 | 62 |
| Meloxicam | Meloxicam | 247 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 236 | 55 |
| Furosemide | Furosemide | 232 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 38 |
| Losartan Potassium | Losartan Potassium | 202 | 43 |
| Potassium Chloride | Potassium Chloride | 202 | 50 |
| Famotidine | Famotidine | 186 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 36 |
| Simvastatin | Simvastatin | 185 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 183 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 182 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 23 |
| Januvia | Sitagliptin Phosphate | 148 | 24 |
| Lorazepam | Lorazepam | 147 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 56 |
| Doxycycline Hyclate | Doxycycline Hyclate | 141 | 112 |
| Buspirone Hcl | Buspirone Hcl | 136 | 36 |
| Tramadol Hcl | Tramadol Hcl | 133 | 24 |
| Glipizide Er | Glipizide | 131 | 20 |
| Eliquis | Apixaban | 130 | 26 |
| Carvedilol | Carvedilol | 123 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 119 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 114 | 28 |
| Atenolol | Atenolol | 112 | 19 |
| Ozempic | Semaglutide | 112 | 19 |
| Sertraline Hcl | Sertraline Hcl | 107 | 20 |
| Methylprednisolone | Methylprednisolone | 102 | 82 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 100 | 19 |
| Clonazepam | Clonazepam | 98 | 11 |
| Allopurinol | Allopurinol | 92 | 21 |
| Diazepam | Diazepam | 89 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 20 |
| Prednisone | Prednisone | 85 | 57 |
| Ibuprofen | Ibuprofen | 83 | 21 |
| Glipizide | Glipizide | 79 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 15 |
| Meclizine Hcl | Meclizine Hcl | 67 | 23 |
| Alendronate Sodium | Alendronate Sodium | 64 | 13 |
| Baclofen | Baclofen | 64 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 17 |
| Montelukast Sodium | Montelukast Sodium | 64 | 15 |
| Alprazolam | Alprazolam | 60 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 60 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 59 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 13 |
| Bupropion Xl | Bupropion Hcl | 57 | suppressed |
| Ezetimibe | Ezetimibe | 55 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 13 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 11 |
| Finasteride | Finasteride | 48 | 15 |
| Synthroid | Levothyroxine Sodium | 47 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 26 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 33 |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 30 |
| Fluconazole | Fluconazole | 34 | 20 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Nitroglycerin | Nitroglycerin | 27 | 15 |
| Linzess | Linaclotide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Flovent Hfa | Fluticasone Propionate | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Sulindac | Sulindac | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $521.16 · 29 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, INSPIRE, Korlym, MOUNJARO, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error